",is there hope that 208 might also be of use to those who do not have low HDL and diabetes,,,,,patients or sub groups outside of our more narrowly defined poulation?"

Yes, there will be A LOT of analysis, both pre-specified and post-hoc, of the BETonMACE data. For the primary MACE outcome, they already plan to analyze by statin type, days since ACS event, above and below median lipids (LDL-C, HDL-C, triglycerides), above and below median HbA1c, and eGFR above and below 60 mL/min. These will be very informative going forward. Plus I'm sure there will be a ton of post-hoc analyses too on other comparisons not pre-specified. If BETonMACE is successful, expect tons of follow up analysis and expect future trials to expand the label based upon results of these pre-specified and post-hoc analyses. All in my opinion. DYODD.

BearDownAZ